Retirement of Yves Berthiaume, Vice President, Clinic and Clinical Research

Dec. 14 2018 | Internal community

All news

On December 13, the Montreal Clinical Research Institute (IRCM) paid tribute to Yves Berthiaume, Vice President, Clinical and Clinical Research, on the occasion of his retirement.

“Dr. Berthiaume has been a highly valued colleague, as wella s a senior clinician and an accomplished researcher,” said Tarik Möröy, President and Scientific Director of the IRCM. “As Vice President, Clinic and Clinical Research, Dr. Berthiaume was a member of the management committee of the Institute and instrumental in the establishment of the Institute's Centre for Research on Rare and Genetic Diseases in Adults, which opened in 2016. Since then, the Institute has opened three new clinics to treat primary immunodeficiencies, rare kidney diseases and genetic dyslipidemia. The Institute’s community, including the patients of the IRCM Clinic, thank him for his excellent work, as well as his engagement and support to develop the clinical research activities at the Institute.”

Yves Berthiaume graduated in medicine from Université de Sherbrooke. He specializes in pulmonology and physiology, and completed his postdoctoral training at the University of California, San Francisco. Renowned pulmonologist, Dr. Berthiaume has published over 100 scientific articles in prestigious journals. His research interests focus on the role of pulmonary epithelium in the pathophysiology of diseases such as cystic fibrosis or pulmonary oedema. 

Dr. Berthiaume is also a pulmonologist and an active member of the Centre hospitalier de l’Université de Montréal (CHUM)’s cystic fibrosis clinic, an associate researcher at the CHUM Research Centre, and a professor at Université de Montréal’s Faculty of Medicine. From 2012 to 2018, he managed a cystic fibrosis clinic located at the IRCM as well as the Institute’s Cellular and Molecular Lung Biology Research Unit. 

Sophie Bernard, Director of the Lipids, Nutrition and Cardiovascular Prevention Clinic and of the Genetic Dyslipidemias Clinic, will act as Vice President, Clinic and Clinical Research starting January 1st, 2019.